Adult-Onset Myasthenia Gravis: Comprehensive Disease-Characteristics Report

Scope. This report concerns acquired adult-onset autoimmune myasthenia gravis (MG), not congenital myasthenic syndromes (CMS), Lambert–Eaton myasthenic syndrome, or transient neonatal MG. Evidence is labeled as human clinical, human genetic/computational, model-organism, or in vitro. Unless otherwise stated, facts are aggregated disease-level knowledge rather than observations from an individual electronic health record.

Executive summary

Adult-onset MG is a chronic, heterogeneous, T-cell-dependent, autoantibody-mediated disorder of the postsynaptic neuromuscular junction (NMJ). Its defining manifestation is fluctuating, fatigable weakness affecting ocular, bulbar, axial, limb, and sometimes respiratory muscles. Approximately 80% of generalized cases have acetylcholine-receptor antibodies (AChR-Ab); MuSK antibodies account for about 5%–8% of AChR-negative cases, while LRP4-associated and seronegative disease are less common. The 2024 JCI review accurately summarizes the spectrum as weakness “ranging from limited ocular muscle involvement to life-threatening respiratory failure.” Published June 2024; DOI/URL. (kaminski2024myastheniagravisthe pages 1-2)

The disease is not ordinarily monogenic. HLA and immune-regulatory loci confer polygenic susceptibility, whereas pathogenic germline variants in CHRNE, RAPSN, DOK7, MUSK, LRP4, AGRN, and related genes cause CMS and should not be misclassified as causal variants for autoimmune adult-onset MG. Treatment has shifted from nonspecific immunosuppression toward antibody-endotype-directed complement C5 inhibition, FcRn blockade, and B-cell depletion. Nevertheless, conventional therapy, thymectomy in selected AChR-positive disease, and IVIG/plasma exchange in crisis remain central. (OpenTargets Search: myasthenia gravis, kaminski2024myastheniagravisthe pages 1-2, wiendl2023guidelineforthe pages 2-3)

1. Disease information

Definition and classification

MG is an acquired autoimmune disorder in which antibodies against postsynaptic proteins reduce the safety factor for neuromuscular transmission. Clinical classification integrates:

• distribution: ocular versus generalized;
• onset: early-onset versus late-onset, commonly separated at 50 years, although studies use 40–60-year cutoffs;
• antibody: AChR, MuSK, LRP4, or seronegative;
• thymic pathology: thymoma-associated, hyperplastic, or non-thymomatous;
• special trigger: immune-checkpoint-inhibitor-associated MG. (antonioni2023theincidenceof pages 1-2, kaminski2024myastheniagravisthe pages 2-4)

Identifiers and synonyms

• MONDO: adult-onset myasthenia gravis MONDO:0018324; parent MG MONDO:0009688.
• ICD-10-CM: G70.0, myasthenia gravis without acute exacerbation; more specific national extensions distinguish exacerbation/crisis.
• ICD-11: classified under myasthenia gravis within disorders of the neuromuscular junction.
• MeSH: Myasthenia Gravis.
• Orphanet: myasthenia gravis is represented as a rare autoimmune NMJ disease; national subtype coding varies.
• Common labels: autoimmune MG, acquired MG, adult MG, adult-onset MG, ocular MG, generalized MG (gMG), late-onset MG (LOMG), AChR-MG, MuSK-MG, LRP4-MG, and seronegative MG. “Late-onset” is a subtype rather than a synonym for every adult case.

The reusable ontology mapping is summarized below.

Table: This table summarizes knowledge-base-ready entities for adult-onset autoimmune myasthenia gravis, including disease identifiers, phenotypes, anatomy, mechanisms, susceptibility genes versus non-causal CMS genes, and treatment targets/classes. It is designed to support ontology mapping and evidence-linked curation.

2. Etiology, risk, protective factors, and gene–environment interaction

Primary cause

The proximal cause is loss of immune tolerance followed by production of pathogenic antibodies against NMJ proteins. AChR antibodies are usually complement-fixing IgG1/IgG3; MuSK antibodies are predominantly IgG4 and disrupt protein–protein signaling rather than fixing complement. Thymic germinal-center-like reactions and abnormal thymic epithelial biology are important in many AChR-positive cases. (vakrakou2023immunotherapiesinmuskpositive pages 1-2, kaminski2024myastheniagravisthe pages 2-4, wiendl2023guidelineforthe pages 2-3)

Genetic susceptibility

Human genetic evidence. A 2022 GWAS meta-analysis of 1,401 cases and 3,508 controls confirmed TNFRSF11A rs4369774 (OR 1.40, p=1.09×10⁻¹³), identified HLA-DQA1 rs34481484 (OR 2.11, p=3.72×10⁻⁹), and implicated CTLA4, AGRN, and ISG15. Estimated SNP heritability was 0.37 overall, 0.64 in early-onset and 0.53 in late-onset disease, supporting substantial but non-Mendelian inherited susceptibility. Published August 2022; DOI/URL. (topaloudi2022myastheniagravisgenomewide pages 8-12)

A dedicated LOMG GWAS of 532 AChR-positive cases and 2,128 controls found TNFRSF11A rs4574025 (OR 1.42, p=3.9×10⁻⁷), protective ZBTB10 rs6998967 (OR 0.53, p=8.9×10⁻¹⁰), and suggestive PTPN22 R620W/rs2476601 association (OR 1.62, p=6.5×10⁻⁶). HLA-DQA1*05:01 showed opposite effects in LOMG (OR 0.54) and early-onset MG (OR 2.82), demonstrating that onset-defined subgroups have different immunogenetic architectures. Published November 10, 2015; DOI/URL. (seldin2015genomewideassociationstudy pages 1-2)

Interpretation: these are susceptibility alleles, not clinically deterministic pathogenic variants. Penetrance, carrier frequency, anticipation, germline mosaicism, consanguinity, and Mendelian recurrence-risk concepts are therefore not applicable in the way they are for CMS. Open Targets specifically links PTPN22 to adult-onset MG and identifies therapeutically validated targets including C5, FCGRT, and ACHE; target association should not be equated with germline causation. (OpenTargets Search: myasthenia gravis)

Non-genetic risk and trigger factors

• Age and sex: early adult AChR-MG has a female predominance of about 3:1 and peaks in the third decade; late-onset disease peaks around the sixth decade and has a male predominance (women:men about 2:3). MuSK-MG also has a female bias and often peaks around the fourth decade. (kaminski2024myastheniagravisthe pages 2-4)
• Thymoma: a causal immune-tolerance context in a minority of generalized AChR-MG; neoplastic thymic epithelial cells may inadequately express HLA class II and AIRE-dependent self-antigens. Approximately 10% of generalized AChR-positive MG had thymoma in older European series, while one recent Ferrara cohort reported 17%. (antonioni2023theincidenceof pages 1-2, seldin2015genomewideassociationstudy pages 1-2)
• Infection: respiratory and systemic infections commonly precipitate exacerbation or crisis. SARS-CoV-2-associated onset has been reported, but a population study concluded that causal evidence remains inconclusive. (antonioni2023theincidenceof pages 1-2)
• Iatrogenic triggers: immune-checkpoint inhibitors can induce rapidly severe MG, sometimes with myositis/myocarditis overlap. Magnesium, aminoglycosides, fluoroquinolones, macrolides, neuromuscular blockers, and selected antiarrhythmics or beta-blockers may worsen transmission; associations vary in strength and do not imply that every exposed patient will deteriorate. (kaminski2024myastheniagravisthe pages 2-4)
• Pregnancy/postpartum: disease activity may improve, worsen, or remain stable during pregnancy; postpartum exacerbation is recognized. Maternal IgG may cause transient neonatal MG, but this is passive antibody transfer, not inheritance.

Protective factors

No validated genetic protective variant or diet prevents MG. The ZBTB10 signal above is statistically protective but is not an actionable intervention. Smoking, alcohol, exercise, specific diets, or supplements have no established primary-preventive effect. Vaccination, infection control, sleep, graded exercise, and medication review are best viewed as tertiary prevention of exacerbation and treatment complications—not prevention of autoimmune onset. (seldin2015genomewideassociationstudy pages 1-2, wiendl2023guidelineforthe pages 17-19)

Gene–environment interaction

The prevailing model is polygenic immune susceptibility plus a context that disrupts tolerance—thymic pathology, infection, age-related immune remodeling, or checkpoint blockade—followed by autoreactive T/B-cell expansion. Direct, replicated locus-by-exposure interaction estimates remain sparse; most claimed environmental associations are observational or case-based rather than proven G×E effects.

3. Phenotypes

These manifestations and frequencies are supported by the 2024 JCI review and 2023 guideline. The guideline emphasizes that fatigue may occur independently of neuromuscular fatigability and that only cross-sectional evidence supports its association with depression and reduced QoL. (kaminski2024myastheniagravisthe pages 1-2, wiendl2023guidelineforthe pages 17-19)

Recommended outcome annotations are MG-ADL (0–24), QMG (0–39), MGC, MG-QoL15r (0–30), MGFA class, and post-intervention status. These measure different biological or patient-centered domains and are not interchangeable. (sikorski2023serummetabolomicsof pages 1-2, NCT06298552 chunk 1)

4. Genetic and molecular information

Causal genes and variants

There is no single causal gene, canonical pathogenic variant, chromosomal abnormality, or inheritance pattern for ordinary adult autoimmune MG. Accordingly:

• ACMG pathogenic/likely pathogenic/VUS classification, somatic-versus-germline status, population allele frequency, carrier frequency, karyotype, FISH, CMA, repeat-expansion, mitochondrial, WES, and WGS testing are not routine MG diagnostics.
• If onset was congenital/childhood, there is a family history, fixed weakness, dysmorphism, episodic apnea, or antibody/electrophysiologic findings are atypical, evaluate CMS genes such as CHRNE, CHRNA1, CHRNB1, CHRND, RAPSN, DOK7, MUSK, LRP4, AGRN, COLQ, CHAT, GFPT1, and SCN4A. Those variants cause genetic myasthenic syndromes, not acquired autoimmune MG. (OpenTargets Search: myasthenia gravis, wiendl2023guidelineforthe pages 3-4)

Susceptibility and modifier candidates

HLA-DRB1, HLA-DQA1, HLA-B, HLA-A, TNFRSF11A, PTPN22, CTLA4, TNIP1, ZBTB10, AGRN, and ISG15 are susceptibility candidates. No modifier gene has sufficient evidence for routine severity prediction. Genetic architecture differs by age, sex, antibody status, and thymic pathology. (topaloudi2022myastheniagravisgenomewide pages 4-8, topaloudi2022myastheniagravisgenomewide pages 8-12, seldin2015genomewideassociationstudy pages 1-2)

Epigenetics and chromosomal changes

Altered miRNA expression, DNA methylation, and lymphocyte/thymic transcriptional programs have been described, but no epigenetic mark is validated for diagnosis or treatment selection. Large chromosomal abnormalities are not characteristic. Thymoma has tumor genomic alterations, but these belong to the neoplasm and are not defining germline lesions of MG.

5. Environmental information

No toxin, radiation exposure, pollution source, occupation, diet, smoking pattern, alcohol exposure, or exercise behavior has been established as a necessary or sufficient cause. The most actionable environmental information concerns exacerbation:

1. infection, fever, surgery, sleep deprivation and major physiological stress can increase weakness;
2. excessive heat may worsen transmission transiently;
3. medications that impair presynaptic release, postsynaptic responsiveness, or respiratory reserve require review;
4. immune-checkpoint blockade can induce a distinct, rapidly severe autoimmune phenotype;
5. evidence linking SARS-CoV-2 infection or vaccination to new-onset MG remains insufficient for causal population-level inference. In Ferrara, incidence was 2.7/100,000/year in 2008–2018 versus 2.1/100,000 during 2019–2022, a non-significant reduction rather than an increase. Published December 30, 2023; DOI/URL. (antonioni2023theincidenceof pages 1-2)

6. Mechanism and pathophysiology

Causal chain

Upstream: polygenic susceptibility/thymic abnormality or acquired trigger → defective central/peripheral tolerance → autoreactive CD4 T-cell help → B-cell, plasmablast and plasma-cell expansion → pathogenic IgG production.

Endotype-specific effector stage:

• AChR-MG: IgG1/IgG3 binds clustered nicotinic AChR → classical complement activation and C5 cleavage → C5b-9 membrane-attack-complex injury; antibody cross-linking also accelerates receptor endocytosis (“antigenic modulation”), while a subset directly blocks acetylcholine binding. (kaminski2024myastheniagravisthe pages 2-4)
• MuSK-MG: predominantly functionally monovalent IgG4 blocks LRP4–MuSK interaction → impaired MuSK phosphorylation and rapsyn-dependent AChR clustering. Because IgG4 does not efficiently fix complement, C5 inhibitors are mechanistically inappropriate for this endotype. The 2023 review states that IgG4 antibodies exert pathogenicity “via interfering with the interaction between their targets and binding partners.” Published July 2023; DOI/URL. (vakrakou2023immunotherapiesinmuskpositive pages 1-2)
• LRP4-MG: antibodies interfere with agrin–LRP4–MuSK signaling; complement contribution is less clearly defined.

Downstream: fewer functional AChRs, damaged junctional folds and reduced sodium-channel density → smaller end-plate potentials → repeated activity lowers the end-plate potential below action-potential threshold → progressive failure of muscle-fiber recruitment → fatigable weakness, dysphagia, diplopia, or ventilatory failure. (kaminski2024myastheniagravisthe pages 2-4)

Relevant ontology suggestions

• GO biological process: complement activation; membrane attack complex assembly; receptor-mediated endocytosis; regulation of acetylcholine-receptor clustering; cholinergic synaptic transmission; skeletal-muscle contraction; B-cell activation; T-cell activation; immunoglobulin production.
• GO cellular component: neuromuscular junction; postsynaptic membrane; acetylcholine-gated channel complex; membrane attack complex; immunological synapse.
• Cell Ontology: B cell, memory B cell, plasmablast, plasma cell, CD4-positive alpha-beta T cell, regulatory T cell, thymic epithelial cell, skeletal-muscle fiber, alpha motor neuron.

Molecular profiling and advanced technologies

• Metabolomics/lipidomics—human exploratory: an MGTX-serum study found higher phospholipids associated with treatment response. Histidine, free fatty acid 13:0, γ-cholestenol and guanosine predicted a strict corticosteroid-response phenotype with AUC 0.90. The authors stress that the panel “can now undergo validation”; it is not a clinical biomarker. Published October 10, 2023; DOI/URL. (sikorski2023serummetabolomicsof pages 1-2)
• Single-cell/spatial studies—human research: thymic and peripheral immune-cell studies identify heterogeneous autoreactive B/T-cell states and germinal-center niches. They refine endotyping but have no approved diagnostic use. (kaminski2024myastheniagravisthe pages 10-10, kaminski2024myastheniagravisthe pages 10-11)
• Proteomics/transcriptomics: candidate cytokine, chemokine, complement and B-cell signatures are reported, but inter-cohort validation is incomplete.
• Functional platforms—in vitro: cell-based antibody assays and human stem-cell-derived NMJs reproduce native antigen conformation and permit functional/pathogenicity testing and drug screening. (kaminski2024myastheniagravisthe pages 1-2)
• Spatial transcriptomics, CRISPR screens, routine liquid biopsy: investigational or not established for adult MG.

7. Anatomical structures affected

• Primary organ/system: peripheral neuromuscular system; voluntary skeletal muscle is functionally denervated at the NMJ despite structurally intact motor axons.
• Primary site: postsynaptic motor end plate/neuromuscular junction—suggested UBERON term labels: neuromuscular junction, skeletal muscle organ, extraocular muscle, diaphragm, pharyngeal muscle and laryngeal muscle.
• Secondary organ: thymus—hyperplasia or thymoma in relevant AChR-positive subtypes.
• Respiratory system: diaphragm and accessory respiratory muscles are secondarily affected during severe disease; lung parenchyma is not the primary target.
• Subcellular compartments: postsynaptic membrane, junctional folds, AChR complex, MuSK–LRP4 signaling complex, and complement membrane-attack complex.
• Localization/lateralization: ocular findings are often asymmetric and can alternate; generalized weakness is usually bilateral but not necessarily symmetric. (kaminski2024myastheniagravisthe pages 2-4, kaminski2024myastheniagravisthe pages 1-2)

8. Temporal development and natural history

Onset may be insidious, subacute, or—especially after checkpoint inhibitors—rapid. Early adult AChR disease peaks in young women; late-onset disease increasingly affects older men, with the highest recent Ferrara incidence in people over 70. Ocular disease is often operationally classified as persistent ocular MG if it has not generalized for at least two years. (antonioni2023theincidenceof pages 1-2, kaminski2024myastheniagravisthe pages 2-4)

The course is chronic and fluctuating, with exacerbations, treatment-induced remission, pharmacologic remission, minimal manifestations, or persistent active/refractory disease. A 2024 review estimated relapse in 18%–34% and nonresponse to traditional immunosuppressants in about 10%, although definitions and cohorts vary. (zhong2024initiationresponsemaximized pages 1-2)

The greatest risk of ocular-to-generalized conversion is early in the disease course; early disease control and thymectomy, when indicated, represent important intervention windows. Abrupt withdrawal of immunotherapy can cause recurrence or crisis. Spontaneous permanent remission occurs but cannot be predicted reliably; most patients require prolonged monitoring and many require long-term immunotherapy. (wiendl2023guidelineforthe pages 3-4, wiendl2023guidelineforthe pages 9-10)

9. Inheritance, epidemiology, and population

Epidemiology

A meta-analysis cited in the Ferrara population study estimated prevalence at 7.7/100,000 and incidence at 0.5/100,000 person-years; recent annual incidence estimates commonly range from 0.3 to 3.0/100,000. A broader 2023 review estimated approximately 700,000 affected worldwide, median prevalence around 10/100,000, and regional incidence ranging from about 0.4/100,000 in Norway to 2.1/100,000 in Italy and Taiwan. Differences reflect age structure, ascertainment, diagnostic access and case definitions. (huang2023myastheniagravisnovel pages 1-3, antonioni2023theincidenceof pages 1-2)

Ferrara’s complete-enumeration study identified 106 incident cases in 2008–2018 (2.7/100,000/year) and 29 in 2019–2022 (2.1/100,000/year), with rising late-onset and declining early-onset disease. (antonioni2023theincidenceof pages 1-2)

Demographics and inheritance

• Early-onset AChR-MG: women:men approximately 3:1, peak third decade.
• LOMG: male predominance, peak sixth decade and increasing incidence among those over 70.
• MuSK-MG: female-biased, often younger/middle adult onset, bulbar-predominant.
• Thymoma MG: approximately equal sex ratio or slight male bias, peak near fifth decade. (kaminski2024myastheniagravisthe pages 2-4)

Inheritance is multifactorial/polygenic with low absolute familial recurrence, variable expression, and incomplete/age-dependent susceptibility—not autosomal dominant, recessive, X-linked, or mitochondrial. Anticipation, carrier screening, founder-mutation screening, and consanguinity effects are not established. Geographic differences in antibody and thymoma distributions occur, but variant-specific geographic prediction is not clinically mature.

10. Diagnostics

Clinical and laboratory workflow

1. Identify fluctuating, fatigable ocular, bulbar, limb, axial, or respiratory weakness with preserved sensation and usually normal reflexes.
2. Test serum AChR binding antibodies; where appropriate add blocking/modulating assays or a clustered-AChR cell-based assay.
3. If AChR-negative, test MuSK-Ab; then consider LRP4-Ab and specialized cell-based assays.
4. Perform low-frequency repetitive nerve stimulation (RNS) and/or single-fiber EMG (SFEMG), targeting clinically involved muscles. The 2024 review reports that RNS/SFEMG confirms approximately 90% of seronegative clinically suspected cases. (kaminski2024myastheniagravisthe pages 1-2)
5. Chest CT or MRI for every confirmed patient to evaluate thymoma. (wiendl2023guidelineforthe pages 3-4)
6. Assess respiratory status during bulbar/generalized deterioration using forced vital capacity, negative inspiratory force, oxygenation and blood gases; normal oxygen saturation does not exclude impending ventilatory failure.
7. Use MGFA class, MG-ADL, QMG, MGC and MG-QoL15r longitudinally.

The guideline’s exact summary is: “The diagnosis of MG is based on the history and physical findings of fatigable and fluctuating muscle weakness,” confirmed through autoantibodies, electrophysiology and/or pharmacological testing. Published 2023; DOI/URL. (wiendl2023guidelineforthe pages 3-4)

Imaging, biopsy, genetic and omics tests

• CT/MRI evaluates thymoma but does not diagnose junctional transmission failure.
• Muscle biopsy is generally unnecessary; if performed, it may be normal or nonspecific and is mainly used to investigate myopathy.
• WES/WGS/panels are reserved for suspected CMS or alternative genetic neuromuscular disease.
• CMA, karyotype, FISH, mtDNA and repeat-expansion tests have no routine role.
• Transcriptomic, proteomic, metabolomic and epigenomic tests remain research tools. (sikorski2023serummetabolomicsof pages 1-2, wiendl2023guidelineforthe pages 3-4)

Differential diagnosis

Important mimics include Lambert–Eaton syndrome (proximal/autonomic symptoms, facilitation, often reduced reflexes), botulism (pupillary/autonomic involvement and descending paralysis), CMS, mitochondrial/chronic progressive external ophthalmoplegia, oculopharyngeal muscular dystrophy, inflammatory or checkpoint-inhibitor myositis, thyroid eye disease, brainstem stroke, multiple sclerosis, motor-neuron disease, cranial neuropathy and functional neurological disorder. MuSK-MG can resemble bulbar-onset motor-neuron disease; ICI-associated MG should prompt simultaneous creatine kinase, troponin, ECG and cardiac evaluation because of myositis/myocarditis overlap.

Screening

There is no population, newborn, carrier, prenatal, or asymptomatic genetic screening program. Targeted evaluation may be appropriate in thymoma, before/after checkpoint blockade when symptoms arise, or in relatives only if the phenotype suggests CMS rather than autoimmune MG.

11. Outcome and prognosis

Modern MG is usually treatable, and most patients achieve substantial control, but complete stable remission is less common than improvement or minimal manifestations. Survival approaches the general population in well-managed patients, although older age, respiratory crisis, aspiration, infection, thymoma, severe bulbar disease, and treatment toxicity increase risk. Contemporary literature does not support a single universal 5- or 10-year survival percentage because cohorts differ markedly.

Morbidity includes fluctuating disability, aspiration, crisis, hospitalization, falls, treatment-associated infection/metabolic disease, anxiety/depression, fatigue and impaired employment. Persistent fatigue can occur in approximately one-third of pharmacologically remitted patients and correlates with poorer QoL. (wiendl2023guidelineforthe pages 17-19)

Poorer prognosis is associated with delayed recognition, severe baseline MGFA class, recurrent crisis, thymoma, older age/comorbidity, MuSK bulbar/respiratory predominance, and insufficient treatment response. AChR antibody concentration alone correlates imperfectly with clinical severity because antibody epitope, subclass and effector mechanism vary. (kaminski2024myastheniagravisthe pages 2-4)

12. Treatment

Staged clinical strategy

1. Symptomatic: pyridostigmine (ACHE inhibition; NCIt term label: pyridostigmine bromide), adjusted to function and tolerability. MuSK-MG may respond poorly and can worsen with excessive cholinesterase inhibition.
2. Conventional disease modification: prednisone/prednisolone, usually with steroid-sparing azathioprine; alternatives include mycophenolate, tacrolimus, cyclosporine or methotrexate. Evidence for some alternatives is mixed, and onset of benefit is delayed. (wiendl2023guidelineforthe pages 9-10)
3. Endotype-directed therapy: C5 inhibitors for complement-mediated AChR-positive gMG; FcRn inhibitors for pathogenic-IgG reduction; rituximab particularly for MuSK-MG.
4. Crisis/severe exacerbation: ICU-level respiratory/bulbar surveillance, treatment of precipitant, IVIG or plasma exchange/immunoadsorption, with ventilatory and aspiration support. (wiendl2023guidelineforthe pages 3-4)

Thymectomy

Thymoma requires complete oncologic thymectomy where feasible. For non-thymomatous AChR-positive generalized MG, MGTX randomized 126 adults aged 18–65 with disease under five years. At three years, thymectomy plus prednisone versus prednisone alone reduced time-weighted QMG (6.15 vs 8.99), alternate-day prednisone (44 vs 60 mg), azathioprine use (17% vs 48%) and exacerbation hospitalization (9% vs 37%), all p<0.001. The abstract concludes: “Thymectomy improved clinical outcomes over a 3-year period.” Published August 11, 2016; PMID 27509100; DOI/URL. (wolfe2016randomizedtrialof pages 1-3)

Guidelines recommend early thymectomy—ideally within two years and no later than five years after diagnosis—for suitable 18–65-year-old AChR-positive generalized patients. It is not routinely recommended for MuSK-MG. (wiendl2023guidelineforthe pages 3-4, wiendl2023guidelineforthe pages 2-3)

Targeted therapies and 2023–2024 developments

• C5 complement inhibition: eculizumab, ravulizumab, and zilucoplan prevent terminal complement/MAC injury. Their strongest rationale is AChR-positive gMG. Meningococcal vaccination and infection-risk mitigation are mandatory; breakthrough invasive infection remains possible. Zilucoplan received US approval in October 2023. (gu2024efficacyandsafety pages 1-2, kaminski2024myastheniagravisthe pages 2-4)
• FcRn blockade: efgartigimod and rozanolixizumab accelerate pathogenic IgG clearance. IV and subcutaneous efgartigimod formulations and rozanolixizumab expanded practical treatment options during 2023–2024. Typical concerns include headache and infection; FcRn blockade lowers total IgG but is not antigen-specific. (zhong2024initiationresponsemaximized pages 1-2, habib2024efficacyandsafety pages 1-2, wiendl2023guidelineforthe pages 2-3)
• MuSK-MG: rituximab is often used earlier because conventional therapy and IVIG may be less effective. Plasma exchange is frequently effective. Rozanolixizumab is approved for AChR- or MuSK-antibody-positive gMG in the US. (vakrakou2023immunotherapiesinmuskpositive pages 1-2, habib2024efficacyandsafety pages 1-2)

In the 21-patient MuSK subgroup of phase III MycarinG, day-43 MG-ADL changes were −7.28 with 7 mg/kg, −4.16 with 10 mg/kg and +2.28 with placebo; differences from placebo were −9.56 and −6.45. Treatment-emergent adverse events occurred in 80.0%, 62.5% and 37.5%, respectively, but there were no serious events or deaths. The small subgroup warrants cautious interpretation. Published 2024; NCT03971422; DOI/URL. (habib2024efficacyandsafety pages 1-2)

A 2024 network meta-analysis of 21 RCTs, 13 drugs and 1,657 patients ranked batoclimab highest for QMG/MGC, rozanolixizumab highest for MG-ADL, and eculizumab highest for MG-QoL15r; indirect SUCRA rankings should not be interpreted as head-to-head superiority because populations and regimens differed. Published October 2024; DOI/URL. (gu2024efficacyandsafety pages 1-2)

Current experimental applications

• Inebilizumab/CD19 depletion: phase III MINT, NCT04524273, 238 AChR- or MuSK-positive adults, with MG-ADL at week 26 as primary outcome. (NCT04524273 chunk 1)
• Efgartigimod in AChR-binding-seronegative gMG: ADAPT SERON, phase III, NCT06298552, 119 participants. (NCT06298552 chunk 1)
• NMD670: phase IIb SYNAPSE-MG, NCT06414954, estimated 84 participants; a muscle chloride-channel-directed symptomatic approach assessed over 21 days. (NCT06414954 chunk 1)
• Anti-CD19 CAR-T: KYV-101/mivocabtagene autoleucel, phase II/III KYSA-6, NCT06193889, estimated 66 treatment-refractory participants. This is an experimental immune-reset strategy, not established care. (NCT06193889 chunk 1)
• Antigen-specific/CAAR-T and RNA/gene approaches: preclinical or early clinical; no approved gene, RNA, stem-cell, or regenerative therapy exists for autoimmune MG. (vakrakou2023immunotherapiesinmuskpositive pages 1-2, keritam2024aclinicalperspective pages 13-13)

Rehabilitation and supportive care

Use individualized aerobic and resistance exercise below the threshold that provokes prolonged weakness; respiratory, swallowing, speech, occupational and physical therapy are indicated by phenotype. Manage aspiration risk, nutrition, sleep, mood, osteoporosis, infection risk and steroid metabolic toxicity. Mechanical ptosis aids, prisms or occlusion may help refractory ocular symptoms. (wiendl2023guidelineforthe pages 17-19)

No validated CPIC/PharmGKB genotype-guided treatment algorithm exists. TPMT/NUDT15 testing may guide azathioprine safety according to general pharmacogenetic practice, but it predicts metabolism/toxicity rather than MG response.

13. Prevention

• Primary prevention: none established; MG is not preventable through routine genetic screening, diet or vaccination.
• Secondary prevention: no asymptomatic population screening. Prompt recognition of ptosis, diplopia, bulbar fatigue or respiratory symptoms reduces diagnostic delay.
• Tertiary prevention: medication reconciliation; infection prevention; completion of indicated vaccines before prolonged immunotherapy; meningococcal vaccination/prophylaxis for C5 blockade; gradual—not abrupt—immunotherapy taper; perioperative planning; crisis education; swallowing and respiratory monitoring. The guideline specifically recommends assessing and completing vaccination history before prolonged immunotherapy. (wiendl2023guidelineforthe pages 9-10)
• Immunization: non-live vaccines are generally appropriate, but timing should account for B-cell-depleting treatment and other immunosuppression. Vaccination-associated MG reports do not outweigh the recognized risk of infection-triggered exacerbation at the population level.
• Counseling: ordinary autoimmune MG does not justify carrier or prenatal testing. Counsel women about pregnancy, medication safety, postpartum exacerbation and transient neonatal MG risk.

14. Natural disease in other species

Naturally occurring acquired autoimmune MG occurs most importantly in dogs (Canis lupus familiaris; NCBI Taxon 9615) and more rarely cats (Felis catus; Taxon 9685). Dogs develop AChR-antibody-associated focal or generalized weakness; megaesophagus with regurgitation and aspiration pneumonia is particularly important and differs from typical human presentation. Thymoma-associated MG occurs in dogs and cats. Some canine breed predispositions are reported, but breed effects vary geographically and are not equivalent to a single orthologous causal mutation.

The same postsynaptic AChR/complement biology and response to anticholinesterase or immunomodulatory treatment make canine disease comparatively informative. However, prominent canine megaesophagus, breed structure, species-specific immune responses and differences in treatment constrain direct extrapolation. Autoimmune MG is not infectious or zoonotic and has no cross-species transmission risk.

15. Model organisms and experimental systems

• Active experimental autoimmune MG (EAMG): mice, rats and rabbits immunized with purified AChR or AChR peptides develop AChR antibodies, complement-mediated endplate injury, decrement and weakness. This is useful for tolerance, complement and therapeutic studies but compresses the chronic, heterogeneous human disease into an induced response.
• Passive-transfer EAMG: transfer of patient or monoclonal AChR/MuSK antibodies into rodents isolates antibody effector mechanisms and permits causal testing. It does not reproduce thymic initiation, long-term T/B-cell evolution or the full human antibody repertoire.
• MuSK models: active immunization or passive IgG transfer reproduces impaired AChR clustering and bulbar/generalized weakness; species and IgG-subclass biology can alter complement and Fc effects.
• Genetic models: knockout/knock-in disruption of Musk, Lrp4, Agrn, Rapsn, or Dok7 elucidates NMJ development but models CMS/developmental failure more directly than acquired autoimmunity.
• In vitro human systems: clustered-AChR cell assays, myotubes, motor-neuron–muscle co-cultures, iPSC-derived NMJs and microfluidic/organoid-like platforms permit patient-IgG testing and therapeutic screening. The 2024 JCI review notes both “robust animal models since the 1970s” and newer human stem-cell-derived NMJ platforms. (kaminski2024myastheniagravisthe pages 1-2)

Relevant resources include MGI, IMPC, IMSR/MMRRC/EMMA for mouse strains, RGD for rats, Cellosaurus for cell lines, and GEO/SRA/Single Cell Portal for omics datasets.

Evidence limitations and expert interpretation

1. Adult-onset MG is an umbrella of biologically distinct endotypes; aggregate prevalence, response and prognosis estimates should not be applied indiscriminately to AChR-, MuSK-, LRP4-, thymoma-, ICI-associated or seronegative disease.
2. Recent network meta-analyses offer useful indirect comparisons but are vulnerable to heterogeneous enrollment, background therapy, outcome timing and antibody subtype. (gu2024efficacyandsafety pages 1-2, zhong2024initiationresponsemaximized pages 1-2)
3. Antibody positivity supports diagnosis but does not alone establish current activity; titer–severity correlation is imperfect. Conversely, negative conventional serology does not exclude MG. (kaminski2024myastheniagravisthe pages 2-4, kaminski2024myastheniagravisthe pages 1-2)
4. Genetics and omics presently support mechanistic stratification and target discovery, not routine prediction of individual onset, prognosis, or drug choice. The promising metabolomic AUC of 0.90 requires external validation. (topaloudi2022myastheniagravisgenomewide pages 8-12, sikorski2023serummetabolomicsof pages 1-2)
5. The authoritative 2023 guideline considers rapid achievement of complete disease control a central goal while emphasizing antibody status, thymic pathology, age, activity and patient-reported outcomes. Precision biologics should complement—not replace—careful diagnosis, crisis prevention, conventional immunotherapy and rehabilitation. (wiendl2023guidelineforthe pages 3-4, wiendl2023guidelineforthe pages 2-3)

References

1. (kaminski2024myastheniagravisthe pages 1-2): Henry J. Kaminski, Patricia Sikorski, S. Isabel Coronel, and Linda L. Kusner. Myasthenia gravis: the future is here. Jun 2024. URL: https://doi.org/10.1172/jci179742, doi:10.1172/jci179742. This article has 134 citations and is from a highest quality peer-reviewed journal.

2. (OpenTargets Search: myasthenia gravis): Open Targets Query (myasthenia gravis, 31 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

3. (wiendl2023guidelineforthe pages 2-3): Heinz Wiendl, Angela Abicht, Andrew Chan, Adela Della Marina, Tim Hagenacker, Khosro Hekmat, Sarah Hoffmann, Hans-Stefan Hoffmann, Sebastian Jander, Christian Keller, Alexander Marx, Arthur Melms, Nico Melzer, Wolfgang Müller-Felber, Marc Pawlitzki, Jens-Carsten Rückert, Ulrike Schara-Schmidt, Christiane Schneider-Gold, Benedikt Schoser, Bettina Schreiner, Michael Schroeter, Bettina Schubert, Jörn-Peter Sieb, Fritz Zimprich, and Andreas Meisel. Guideline for the management of myasthenic syndromes. Therapeutic Advances in Neurological Disorders, Jan 2023. URL: https://doi.org/10.1177/17562864231213240, doi:10.1177/17562864231213240. This article has 204 citations and is from a peer-reviewed journal.

4. (antonioni2023theincidenceof pages 1-2): Annibale Antonioni, Emanuela Maria Raho, Domenico Carlucci, Elisabetta Sette, Riccardo De Gennaro, Jay Guido Capone, Vittorio Govoni, Ilaria Casetta, Maura Pugliatti, and Enrico Granieri. The incidence of myasthenia gravis in the province of ferrara, italy, in the period of 2008–2022: an update on a 40-year observation and the influence of the covid-19 pandemic. Journal of Clinical Medicine, 13:236, Dec 2023. URL: https://doi.org/10.3390/jcm13010236, doi:10.3390/jcm13010236. This article has 6 citations.

5. (kaminski2024myastheniagravisthe pages 2-4): Henry J. Kaminski, Patricia Sikorski, S. Isabel Coronel, and Linda L. Kusner. Myasthenia gravis: the future is here. Jun 2024. URL: https://doi.org/10.1172/jci179742, doi:10.1172/jci179742. This article has 134 citations and is from a highest quality peer-reviewed journal.

6. (wiendl2023guidelineforthe pages 3-4): Heinz Wiendl, Angela Abicht, Andrew Chan, Adela Della Marina, Tim Hagenacker, Khosro Hekmat, Sarah Hoffmann, Hans-Stefan Hoffmann, Sebastian Jander, Christian Keller, Alexander Marx, Arthur Melms, Nico Melzer, Wolfgang Müller-Felber, Marc Pawlitzki, Jens-Carsten Rückert, Ulrike Schara-Schmidt, Christiane Schneider-Gold, Benedikt Schoser, Bettina Schreiner, Michael Schroeter, Bettina Schubert, Jörn-Peter Sieb, Fritz Zimprich, and Andreas Meisel. Guideline for the management of myasthenic syndromes. Therapeutic Advances in Neurological Disorders, Jan 2023. URL: https://doi.org/10.1177/17562864231213240, doi:10.1177/17562864231213240. This article has 204 citations and is from a peer-reviewed journal.

7. (gu2024efficacyandsafety pages 1-2): Jian Gu, Yue Qiao, Rui Huang, and Shuyan Cong. Efficacy and safety of immunosuppressants and monoclonal antibodies in adults with myasthenia gravis: a systematic review and network meta-analysis. Journal of Translational Medicine, Oct 2024. URL: https://doi.org/10.1186/s12967-024-05751-1, doi:10.1186/s12967-024-05751-1. This article has 14 citations and is from a peer-reviewed journal.

8. (vakrakou2023immunotherapiesinmuskpositive pages 1-2): Aigli G. Vakrakou, Eleni Karachaliou, Elisabeth Chroni, Vasiliki Zouvelou, Dimitrios Tzanetakos, Stavroula Salakou, Marianna Papadopoulou, Socrates Tzartos, Konstantinos Voumvourakis, Constantinos Kilidireas, Sotirios Giannopoulos, Georgios Tsivgoulis, and John Tzartos. Immunotherapies in musk-positive myasthenia gravis; an igg4 antibody-mediated disease. Frontiers in Immunology, Jul 2023. URL: https://doi.org/10.3389/fimmu.2023.1212757, doi:10.3389/fimmu.2023.1212757. This article has 54 citations and is from a peer-reviewed journal.

9. (wiendl2023guidelineforthe pages 17-19): Heinz Wiendl, Angela Abicht, Andrew Chan, Adela Della Marina, Tim Hagenacker, Khosro Hekmat, Sarah Hoffmann, Hans-Stefan Hoffmann, Sebastian Jander, Christian Keller, Alexander Marx, Arthur Melms, Nico Melzer, Wolfgang Müller-Felber, Marc Pawlitzki, Jens-Carsten Rückert, Ulrike Schara-Schmidt, Christiane Schneider-Gold, Benedikt Schoser, Bettina Schreiner, Michael Schroeter, Bettina Schubert, Jörn-Peter Sieb, Fritz Zimprich, and Andreas Meisel. Guideline for the management of myasthenic syndromes. Therapeutic Advances in Neurological Disorders, Jan 2023. URL: https://doi.org/10.1177/17562864231213240, doi:10.1177/17562864231213240. This article has 204 citations and is from a peer-reviewed journal.

10. (kaminski2024myastheniagravisthe pages 10-11): Henry J. Kaminski, Patricia Sikorski, S. Isabel Coronel, and Linda L. Kusner. Myasthenia gravis: the future is here. Jun 2024. URL: https://doi.org/10.1172/jci179742, doi:10.1172/jci179742. This article has 134 citations and is from a highest quality peer-reviewed journal.

11. (seldin2015genomewideassociationstudy pages 1-2): Michael F. Seldin, Omar K. Alkhairy, Annette T. Lee, Janine A. Lamb, Jon Sussman, Ritva Pirskanen-Matell, Fredrik Piehl, Jan J. G. M. Verschuuren, Anna Kostera-Pruszczyk, Piotr Szczudlik, David McKee, Angelina H. Maniaol, Hanne F. Harbo, Benedicte A. Lie, Arthur Melms, Henri-Jean Garchon, Nicholas Willcox, Peter K. Gregersen, and Lennart Hammarstrom. Genome-wide association study of late-onset myasthenia gravis: confirmation of tnfrsf11a and identification of zbtb10 and three distinct hla associations. Molecular Medicine, 21:769-781, Oct 2015. URL: https://doi.org/10.2119/molmed.2015.00232, doi:10.2119/molmed.2015.00232. This article has 86 citations and is from a peer-reviewed journal.

12. (topaloudi2022myastheniagravisgenomewide pages 8-12): Apostolia Topaloudi, Zoi Zagoriti, Alyssa Camille Flint, Melanie Belle Martinez, Zhiyu Yang, Fotis Tsetsos, Yiolanda-Panayiota Christou, George Lagoumintzis, Evangelia Yannaki, Eleni Zamba-Papanicolaou, John Tzartos, Xanthippi Tsekmekidou, Kalliopi Kotsa, Efstratios Maltezos, Nikolaos Papanas, Dimitrios Papazoglou, Ploumis Passadakis, Athanasios Roumeliotis, Stefanos Roumeliotis, Marios Theodoridis, Elias Thodis, Stylianos Panagoutsos, John Yovos, John Stamatoyannopoulos, Konstantinos Poulas, Kleopas Kleopa, Socrates Tzartos, Marianthi Georgitsi, and Peristera Paschou. Myasthenia gravis genome-wide association study implicates agrn as a risk locus. Journal of Medical Genetics, 59:801-809, Aug 2022. URL: https://doi.org/10.1136/jmedgenet-2021-107953, doi:10.1136/jmedgenet-2021-107953. This article has 20 citations and is from a domain leading peer-reviewed journal.

13. (topaloudi2022myastheniagravisgenomewide pages 4-8): Apostolia Topaloudi, Zoi Zagoriti, Alyssa Camille Flint, Melanie Belle Martinez, Zhiyu Yang, Fotis Tsetsos, Yiolanda-Panayiota Christou, George Lagoumintzis, Evangelia Yannaki, Eleni Zamba-Papanicolaou, John Tzartos, Xanthippi Tsekmekidou, Kalliopi Kotsa, Efstratios Maltezos, Nikolaos Papanas, Dimitrios Papazoglou, Ploumis Passadakis, Athanasios Roumeliotis, Stefanos Roumeliotis, Marios Theodoridis, Elias Thodis, Stylianos Panagoutsos, John Yovos, John Stamatoyannopoulos, Konstantinos Poulas, Kleopas Kleopa, Socrates Tzartos, Marianthi Georgitsi, and Peristera Paschou. Myasthenia gravis genome-wide association study implicates agrn as a risk locus. Journal of Medical Genetics, 59:801-809, Aug 2022. URL: https://doi.org/10.1136/jmedgenet-2021-107953, doi:10.1136/jmedgenet-2021-107953. This article has 20 citations and is from a domain leading peer-reviewed journal.

14. (NCT06298552 chunk 1): A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis. argenx. 2024. ClinicalTrials.gov Identifier: NCT06298552

15. (huang2023myastheniagravisnovel pages 1-3): Evelyn Jou-Chen Huang, Meng-Huang Wu, Tsung-Jen Wang, Tsung-Jen Huang, Yan-Rong Li, and Ching-Yu Lee. Myasthenia gravis: novel findings and perspectives on traditional to regenerative therapeutic interventions. Aging and Disease, 14:1070-1092, Dec 2023. URL: https://doi.org/10.14336/ad.2022.1215, doi:10.14336/ad.2022.1215. This article has 23 citations and is from a peer-reviewed journal.

16. (sikorski2023serummetabolomicsof pages 1-2): Patricia Sikorski, Yaoxiang Li, Mehar Cheema, Gil I. Wolfe, Linda L. Kusner, Inmaculada Aban, and Henry J. Kaminski. Serum metabolomics of treatment response in myasthenia gravis. PLOS ONE, 18:e0287654, Oct 2023. URL: https://doi.org/10.1371/journal.pone.0287654, doi:10.1371/journal.pone.0287654. This article has 17 citations and is from a peer-reviewed journal.

17. (wiendl2023guidelineforthe pages 9-10): Heinz Wiendl, Angela Abicht, Andrew Chan, Adela Della Marina, Tim Hagenacker, Khosro Hekmat, Sarah Hoffmann, Hans-Stefan Hoffmann, Sebastian Jander, Christian Keller, Alexander Marx, Arthur Melms, Nico Melzer, Wolfgang Müller-Felber, Marc Pawlitzki, Jens-Carsten Rückert, Ulrike Schara-Schmidt, Christiane Schneider-Gold, Benedikt Schoser, Bettina Schreiner, Michael Schroeter, Bettina Schubert, Jörn-Peter Sieb, Fritz Zimprich, and Andreas Meisel. Guideline for the management of myasthenic syndromes. Therapeutic Advances in Neurological Disorders, Jan 2023. URL: https://doi.org/10.1177/17562864231213240, doi:10.1177/17562864231213240. This article has 204 citations and is from a peer-reviewed journal.

18. (wolfe2016randomizedtrialof pages 1-3): Gil I. Wolfe, Henry J. Kaminski, Inmaculada B. Aban, Greg Minisman, Hui-Chien Kuo, Alexander Marx, Philipp Ströbel, Claudio Mazia, Joel Oger, J. Gabriel Cea, Jeannine M. Heckmann, Amelia Evoli, Wilfred Nix, Emma Ciafaloni, Giovanni Antonini, Rawiphan Witoonpanich, John O. King, Said R. Beydoun, Colin H. Chalk, Alexandru C. Barboi, Anthony A. Amato, Aziz I. Shaibani, Bashar Katirji, Bryan R.F. Lecky, Camilla Buckley, Angela Vincent, Elza Dias-Tosta, Hiroaki Yoshikawa, Márcia Waddington-Cruz, Michael T. Pulley, Michael H. Rivner, Anna Kostera-Pruszczyk, Robert M. Pascuzzi, Carlayne E. Jackson, Guillermo S. Garcia Ramos, Jan J.G.M. Verschuuren, Janice M. Massey, John T. Kissel, Lineu C. Werneck, Michael Benatar, Richard J. Barohn, Rup Tandan, Tahseen Mozaffar, Robin Conwit, Joanne Odenkirchen, Joshua R. Sonett, Alfred Jaretzki, John Newsom-Davis, and Gary R. Cutter. Randomized trial of thymectomy in myasthenia gravis. New England Journal of Medicine, 375:511-522, Aug 2016. URL: https://doi.org/10.1056/nejmoa1602489, doi:10.1056/nejmoa1602489. This article has 789 citations and is from a highest quality peer-reviewed journal.

19. (zhong2024initiationresponsemaximized pages 1-2): Huahua Zhong, Zhijun Li, Xicheng Li, Zongtai Wu, Chong Yan, Sushan Luo, and Chongbo Zhao. Initiation response, maximized therapeutic efficacy, and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis. Frontiers in Neurology, Oct 2024. URL: https://doi.org/10.3389/fneur.2024.1479685, doi:10.3389/fneur.2024.1479685. This article has 13 citations and is from a peer-reviewed journal.

20. (habib2024efficacyandsafety pages 1-2): Ali A. Habib, Sabrina Sacconi, Giovanni Antonini, Elena Cortés-Vicente, Julian Grosskreutz, Zabeen K. Mahuwala, Renato Mantegazza, Robert M. Pascuzzi, Kimiaki Utsugisawa, John Vissing, Tuan Vu, Heinz Wiendl, Marion Boehnlein, Bernhard Greve, Franz Woltering, and Vera Bril. Efficacy and safety of rozanolixizumab in patients with muscle-specific tyrosine kinase autoantibody-positive generalised myasthenia gravis: a subgroup analysis of the randomised, double-blind, placebo-controlled, adaptive phase iii mycaring study. Therapeutic Advances in Neurological Disorders, Jan 2024. URL: https://doi.org/10.1177/17562864241273036, doi:10.1177/17562864241273036. This article has 12 citations and is from a peer-reviewed journal.

21. (NCT04524273 chunk 1): Myasthenia Gravis Inebilizumab Trial. Amgen. 2020. ClinicalTrials.gov Identifier: NCT04524273

22. (NCT06193889 chunk 1): KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis. Kyverna Therapeutics. 2024. ClinicalTrials.gov Identifier: NCT06193889

23. (NCT06414954 chunk 1): Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis. NMD Pharma A/S. 2024. ClinicalTrials.gov Identifier: NCT06414954

24. (kaminski2024myastheniagravisthe pages 10-10): Henry J. Kaminski, Patricia Sikorski, S. Isabel Coronel, and Linda L. Kusner. Myasthenia gravis: the future is here. Jun 2024. URL: https://doi.org/10.1172/jci179742, doi:10.1172/jci179742. This article has 134 citations and is from a highest quality peer-reviewed journal.

25. (keritam2024aclinicalperspective pages 13-13): Omar Keritam, Angela Vincent, Fritz Zimprich, and Hakan Cetin. A clinical perspective on muscle specific kinase antibody positive myasthenia gravis. Frontiers in Immunology, Dec 2024. URL: https://doi.org/10.3389/fimmu.2024.1502480, doi:10.3389/fimmu.2024.1502480. This article has 15 citations and is from a peer-reviewed journal.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

• DOI:10.3390/jcm13010236 (5 mentions) - The Incidence of Myasthenia Gravis in the Province of Ferrara, Italy, in the Period of 2008–2022: An Update on a 40-Year Observation and the Influence of the COVID-19 Pandemic
• shared terms: clinical

Weighed against this report's own most characteristic terms: disease, clinical, genetic, treatment, gene, achr, autoimmune, guideline, generalized, risk, musk, respiratory, weakness, thymic, causal, antibody, patient, effect, complement, muscle.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.